Lanean...
High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
BACKGROUND: Globally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study aims to assess the respective contributions...
Gorde:
| Argitaratua izan da: | BMC Infect Dis |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5217596/ https://ncbi.nlm.nih.gov/pubmed/28061832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-2171-1 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|